The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Subscribe To Our Newsletter & Stay Updated
